Samsung reveals new prices for Galaxy A7/A9

The Samsung Galaxy A7 will now cost SR999 and the Galaxy A9 will now cost SR1,699.
Updated 16 February 2019

Samsung reveals new prices for Galaxy A7/A9

Samsung Electronics has announced new prices and complementary accessories for its Galaxy A7/A9 smartphones to provide its customers with the latest technology at affordable prices, starting Feb. 14. The company said: “These new prices are carefully catered to meet the needs of our loyal customers and provide a convenient variety of the latest smartphones.”

The Samsung Galaxy A7, originally priced at SR1,299 ($346), will now cost SR999. The Galaxy A7 will also be sold with a complementary Samsung Care Card worth SR600. The Samsung Galaxy A9, which was originally priced at SR1,999, will now cost SR1,699. The Galaxy A9 will be sold with a complementary Battery Pack (10,000 mAh) and a Samsung Care Card. The warranty period is valid for 24 months from the date of purchase and the warranty of the screen protection is in accordance with Samsung Care Cards’ terms and conditions.

The Samsung Galaxy A9 is the world’s first smartphone with four rear cameras, with a 24-megapixel camera as the main camera, and a wide angle lens of 120 degrees that helps capture the whole scene, as well as an optical zoom multiplier (2x).


Clinical trials to accelerate adoption of new drug treatments in Saudi Arabia

Updated 27 May 2020

Clinical trials to accelerate adoption of new drug treatments in Saudi Arabia

  • Trials are being led locally as an essential means to verify the safety and effectiveness of a new drug
  • Eli Lilly has a major role to play during the coronavirus disease (COVID-19) pandemic

RIYADH: Clinical trials in Saudi Arabia could speed up the adoption of new drugs locally, a pharmaceutical executive has told Arab News.

“Clinical trials have two very big benefits for the Kingdom. Firstly, they provide data in the long run with respect to safety and efficacy, catered specifically to the Saudi population. Secondly, they impact local investment and build healthcare capabilities,” Managing Director of Eli Lilly Dimitri Livadas said..

Lividas further explained that the clinical trial phase of any new treatment is crucial as it represents the stage between the adoption or rejection of a drug. Working with the Ministry of Health and with a presence in the Kingdom for 42 years, the pharmaceutical company began research trials in the country in 2016, consisting of five pre-marketing activities and three monitoring studies for post-marketing.

Lividas added that the trials are being led locally as an essential means to verify the safety and effectiveness of a new drug before it is put to the market and introduced to patients. The majority of these are focused on diabetes, oncology, immunology, and osteoporosis.

“We genuinely believe that our future is here in Saudi Arabia. We continue to make great progress in having a commercial organization in the Kingdom that is fully staffed by Saudi nationals,” said Lividas.

As a biopharmaceutical company, Eli Lilly has a major role to play during the coronavirus disease (COVID-19) pandemic. It recently announced partnership with AbCellera to develop a treatment for the virus and aims to enter into clinical trials this year.

“I salute the Saudi authorities for their strong measures to contain the spread of COVID-19. I think it is an example to the world on how to do this. I would like to also express my gratitude toward all healthcare professionals who are currently on the frontlines, risking their own health to help others," Lividas said.